Robigo Raises Series A Led by Leaps by Bayer for Engineered Microbial Crop Protection

Robigo Closes Series A

Robigo, a Cambridge, Massachusetts-based agricultural biotechnology company, has raised a Series A round. The round was led by Leaps by Bayer, with participation from Congruent Ventures, Illumina Ventures, SVG Ventures, and Endeavor8. The funding date is September 18, 2026.

What the Company Does

Robigo engineers microbes to protect crops from fungal disease. Its proprietary ARGO platform computationally designs the active ingredients that its engineered, shelf-stable microbes continuously produce and deliver in the field as a one-time seed treatment.

The approach combines computational design with biological delivery: rather than relying on repeated chemical applications, the engineered microbes are intended to produce and deliver protection from a single seed treatment.

Product Pipeline and Launch Timeline

Two products are gearing up for commercial launch in the United States:

• Soybean sudden death syndrome seed treatment — slated for 2028
• Fusarium wilt treatment for lettuce and berries — slated for 2029

Beyond these two lead products, the company plans pipeline expansion into soil-borne pathogens in broad-acre crops.

The Round at a Glance

• Company: Robigo
• Stage: Series A
• Round type: Series A
• Lead investor: Leaps by Bayer
• Participating investors: Congruent Ventures, Leaps by Bayer, Illumina Ventures, SVG Ventures, Endeavor8
• Funding date: September 18, 2026
• Currency: USD

Why It Matters

Fungal disease is a persistent pressure on crop yields, and growers face increasing scrutiny on the tools available to manage it. Robigo's bet is that engineered microbes can deliver protection through a one-time seed treatment, with the active ingredients designed computationally via the ARGO platform.

The investor syndicate reflects a blend of strategic and financial interest. Leaps by Bayer, the lead, is the impact investment arm associated with Bayer. Illumina Ventures brings a genomics-adjacent perspective, while Congruent Ventures, SVG Ventures, and Endeavor8 round out the group.

Commercialization Path

The company has laid out a sequenced launch plan in the United States. The soybean sudden death syndrome seed treatment is slated for 2028, followed by the fusarium wilt treatment for lettuce and berries in 2029. Both are positioned as seed treatments, a delivery format that fits existing grower practices.

After those launches, Robigo intends to expand its pipeline into soil-borne pathogens in broad-acre crops — a larger addressable segment that would extend the platform beyond the initial specialty and row-crop targets.

What Comes Next

With Series A funding in place, Robigo's near-term focus is bringing its two lead products toward commercial launch in the United States in 2028 and 2029, while advancing pipeline expansion into soil-borne pathogens in broad-acre crops. The company's ARGO platform and its engineered, shelf-stable microbes remain the technical foundation for that plan.